Pokonza is a drug owned by Genus Life Sciences Inc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 07, 2039. Details of Pokonza's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12728138 | NA |
Mar, 2039
(12 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Pokonza is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Pokonza's family patents as well as insights into
ongoing legal events
on those patents.
Pokonza's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Pokonza:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation | Children's Hospital Medical Center, Cincinnati | NA | RECRUITING
(Jun 1, 2026) | PHASE2 |
| Matching Perfusion and Metabolic Activity in HFpEF | University of Pennsylvania | NA | RECRUITING
(May 1, 2026) | PHASE2 |
| Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease | University of British Columbia | NA | RECRUITING
(May 1, 2026) | PHASE2 |
Generic Launch
Generic Release Date:
Pokonza's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 07, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Pokonza Generic API suppliers:
Potassium Chloride is the generic name for the brand Pokonza. 56 different companies have already filed for the generic of Pokonza, with Strides Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Pokonza's generic
Alternative Brands for Pokonza
There are several other brand drugs using the same active ingredient (Potassium Chloride) as Pokonza. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Alcon Pharms Ltd |
| ||
| Azurity |
| ||
| Braintree |
| ||
| Fresenius Kabi Usa |
| ||
| Genus Lifesciences |
| ||
| Norgine |
| ||
| Salix Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Potassium Chloride, Pokonza's active ingredient. Check the complete list of approved generic manufacturers for Pokonza
About Pokonza
Pokonza is a drug owned by Genus Life Sciences Inc. Pokonza uses Potassium Chloride as an active ingredient. Pokonza was launched by Genus in 2025.
Approval Date:
Pokonza was approved by FDA for market use on 25 November, 2025.
Active Ingredient:
Pokonza uses Potassium Chloride as the active ingredient. Check out other Drugs and Companies using Potassium Chloride ingredient
Dosage:
Pokonza is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MEQ/15ML | SOLUTION | Prescription | ORAL |